Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2024 Earnings Call Transcript
Operator: Good morning, and welcome to Y-mAbs Therapeutics, Inc.'s Earnings Conference Call for the Fourth Quarter and Full Year 2024.
Y-Mabs Therapeutics Inc. (YMAB)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Polar Capital Brian Ashford-Russell And Tim Woolley | 1,831,000 | $14,336,730 | 0.08% | |
| 2. | Caligan Partners David Johnson | 1,767,982 | $13,843,299 | 3.5% | |
| 3. | Logos Capital Arsani William | 1,000,000 | $7,830,000 | +25% | 0.91% |
| 4. | D E Shaw D. E. Shaw | 615,131 | $4,816,476 | -22% | 0% |
| 5. | Cormorant Asset Management Bihua Chen | 425,000 | $3,327,750 | -71% | 0.18% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.85 | 6,455 | Director | 4,559,233 | 2023-12-11 | Filing | |
| $6.85 | 6,455 | Director | 4,559,233 | 2023-12-11 | Filing | |
| $7.01 | 102,863 | Director | 4,552,778 | 2023-12-11 | Filing | |
| $6.99 | 18,503 | Director | 4,449,915 | 2023-12-08 | Filing | |
| $6.50 | 6,183 | Director | 4,431,412 | 2023-12-07 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.20 | 3,917 | 137,083 | 2025-03-07 | Filing | ||
| $5.23 | 10,810 | 202,721 | 2025-03-07 | Filing | ||
| $12.97 | 30,000 | 67,681 | 2024-09-16 | Filing | ||
| $13.47 | 65,000 | 97,681 | 2024-09-13 | Filing | ||
| $15.37 | 50,000 | 35,600 | 2024-08-28 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,902,025 | $12,855,971 | 0% | |
| 2. | 1,946,509 | $8,623,034 | 0% | |
| 3. | 441,934 | $1,957,768 | 0% | |
| 4. | 277,610 | $1,229,812 | 0% | |
| 5. | 201,776 | $893,867 | 0% |
News See All
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2024 Earnings Call Transcript
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2024 Earnings Call Transcript November 8, 2024Y-mAbs Therapeutics, Inc. reports earnings inline with expectations.
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q2 2024 Earnings Call Transcript
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q2 2024 Earnings Call Transcript August 12, 2024Y-mAbs Therapeutics, Inc. misses on earnings expectations.
Top 10 Holdings of Caligan Partners
Founded in 2017, Caligan Partners is one of the most significant specialty hedge funds.
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q1 2024 Earnings Call Transcript
Operator: Good morning, and welcome to Y-mAbs Therapeutics Inc. Earnings Conference Call for the First Quarter of 2024. At this time, all participants are in a listen-only mode.
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2023 Earnings Call Transcript
Operator: Good morning and welcome to the Y-mAbs Therapeutics Earnings Conference Call for the Fourth Quarter and Full Year of 2023. At this time, all participants are in a listen-only mode.
5 Most Promising Cancer Stocks According to Analysts
In this piece, we will take a look at the five most promising cancer stocks according to analysts.
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2023 Earnings Call Transcript
Operator: Good morning and welcome to Y-mAbs Therapeutics Third Quarter 2023 Earnings Conference Call. Please note that today’s event is being recorded.
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q2 2023 Earnings Call Transcript
Operator: Good morning, and welcome to the Y-mAbs Therapeutics, Inc.’s Earnings Conference Call for the Second Quarter of 2023. At this time, all participants are in a listen-only mode.
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2022 Earnings Call Transcript
Operator: Good morning, and welcome to the Y-mAbs Therapeutics, Inc.'s Earnings Call for the Fourth Quarter 2022. As a reminder, today's conference will be recorded.
Billionaire Hedge Funds
